Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate:: A brief preliminary report

Nutrition

Volumn 19, Issue 10, 2003, Pages 903-904

  De Luis, Daniel A ^a   Bachiller, P ^b   Aller, R ^b   Bouza, J Eiros ^b   Izaola, O ^b  

^a NONE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTILIPEMIC AGENT; CHOLESTEROL; FENOFIBRATE; GLUCOSE; INDINAVIR; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LABORATORY TEST; LYMPHOCYTE COUNT; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STUDENT T TEST; T LYMPHOCYTE; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0141953221     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(03)00164-3     Document Type: Article

References (12)

1. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.D., Fuhrer J., Satten G.A. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 338:1998;853.
2. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12:1998;F51.
3. De Luis D.A., Aller R., Bachiller P., Tortosa J.I. Reversibilidad de hiperlipemia intensa secundaria a indinavir con fenofibrato micronizado. Med Clin (Barc). 113:1999;716.
4. De Luis D.A., Bachiller P., Aller R. Fenofibrate in hyperlipidemia secondary to HIV protease inhibitors. Nutrition. 17:2001;414.
5. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 351:1998;1881.
6. Wentworth J.M., Burris T.P., Chatterjee V.K. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. J Endocrinol. 164:2000;R7.
7. Weil A., Caldwell J., Strolin M., Dostert P. Species differences in the metabolism disposition of fenofibrate. De Paoletti R., et al. Drugs affecting lipid metabolism. 1987;324 Springer-Verlag, Berlin.
8. Caramelli B., de Bernoche C.Y., Sartori A.M., Sposito A.C., Santos R.D. Hyperlipidemia related to the use of HIV-protease inhibitors natural history and results of treatment with fenofibrate . Braz J Infect Dis. 6:2001;332.
9. 14C-fenofibrate in human volunteers. Drug Metab Disp. 18:1990;115.
10. Kloer H.U. Structure and biochemical effects of fenofibrate. Am J Med. 83:1987;3.
11. Baldini F., Di Giambenedetto S., Cingolani S., et al. Efficacy and tolerability of pravastatin for treatment of HIV-1 protease inhibitor-associated hyperlipidemia a pilot study . AIDS. 14:2000;1660.
12. Moyle G.J., Lloyd M., Reynolds B., Baldwin C., Mandalia S., Gazzard B.G. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS. 15:2001;1503.